- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02583659
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
Study Overview
Status
Conditions
Detailed Description
Establish a clinical database for the advanced gastric cancer patients treated with first-line combined chemotherapy in Tongji hospital.
1.1.Data including age, gender, smoking state, karnofsky performance score(KPS), disease history, clinical stage, primary tumor site, metastasis site, surgery, first-line chemotherapy, therapy after failure of first-line treatment, radiotherapy, toxicity, survival time, the time of free of progress, response were collected.
1.2.The peripheral blood samples were collected for further biomarker reserch.
- Kaplan-Meier and Cox model will be used to analyze the overall survival(OS) and progression-free survival(PFS) of advanced gastric cancer.
- Extract Deoxyribonucleic acid(DNA) from the the peripheral blood and research biomarkers related to the first-line combined chemotherapy for AGC.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
Principal Investigator:
- Xianglin Yuan, MD,PHD
-
Contact:
- Xianglin Yuan, MD,PHD
- Phone Number: 1 13667241722
- Email: yxl@medmail.com.cn
-
Contact:
- Suxian Wei, Master
- Phone Number: 1 15927421058
- Email: wsxattj@126.com
-
Sub-Investigator:
- Suxian Wei, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma;
- Unresectable locally advanced, or recurrent, or metastasis disease;
- Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed.
- Life expectancy of at least 3 months;
- ECOG score 0-2;
- Voluntarily signed the informed consent.
Exclusion criteria:
- Previously treated with first-line chemotherapy;
- First-line chemotherapy with single drug.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Combined chemotherapy
AGC patients treated with first-line combined chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival(OS) . overall survival Overall survival(OS)
Time Frame: From date of enrollment until the date of death from any cause, assessed up to 60 months
|
From date of enrollment until the date of death from any cause, assessed up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival(PFS)
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
|
Objective response rate(ORR)
Time Frame: The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of complete remission (CR) rate and partial remission (PR) rate. Response will be measured through first-line treatment completion, up to 1 year
|
|
Disease control rate(DCR)
Time Frame: The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: Through first-line treatment completion,up to 24 weeks.
|
Through first-line treatment completion,up to 24 weeks.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xianglin Yuan, MD,PHD, Tongji Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJCC004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.